The American Society of Clinical Oncology (ASCO) hosts an annual meeting every spring. At this meeting, oncologists, physicians, researchers, industry members, advocacy organizations (like GO2,) patients, and caregivers come together to share and learn about the latest and most exciting news in the cancer field. While ASCO covers all cancer types, lung cancer was at the top of this year’s discussions. 

The Lung Cancer Living Room’s annual “Best of ASCO” discussion is always one of GO2’s most–watched episodes. It’s an opportunity for our community to learn about the most up-to-date discoveries and clinical advancements and gain real-time insights into the innovative research driving progress in lung cancer. 

This year, GO2 for Lung Cancer’s Chief Patient Officer, Danielle Hicks, was joined by Dr. Roy S. Herbst from Yale Cancer Center to discuss the most promising research presented at ASCO and what it may mean for the future of lung cancer care.  

Speakers:    
  • Roy S. Herbst, MD, PhD, Ensign Professor of Medicine; Professor of Pharmacology; Chief of Medical Oncology, Smilow Cancer Hospital; Deputy Director, Yale Cancer Center; Assistant Dean for Translational Research, Yale School of Medicine
  • Danielle Hicks, Chief Patient Officer, GO2 for Lung Cancer    
Discussed in this episode:   

Read all of the abstracts Dr. Herbst discussed during this Living Room here. 

  • Immunotherapy 
    • Evoke-01 PH lll Study – non-small cell lung cancer (NSCLC) previously treated with platinum-based chemotherapy and PD-L1 inhibitors 
    • OptiTROP-Lung01 PH ll Study – Sacituzumab (tirumotecan) in combination with KL-A167 (anti-PD-L1) as first-line treatment for patients with advanced NSCLC
  • EGFR 
    • LAURA Study – Tagrisso (osimertinib) following chemoradiation for people with stage 3 (lll) EGFR-positive NSCLC who are not candidates for surgery  
    • Paloma PH ll Study – Rybrevant (amivantamab) plus Lazertinib (leclaza) in patients with EGFR-mutant lung cancer and active central nervous system disease 
    • CHRYSALIS ll Study – Rybrevant (amivantamab) plus Lazertinib (leclaza) in typical EGFR-mutated advanced NSCLC 
    • Mariposa Study (secondary analysis) PH lll – Rebrevant (amivantamab) plus Lazertinib (leclaza) vs Tagrisso (osimertinib) in first-line EGFR-mutated advanced NSCLC with biomarkers of high-risk disease 
    • Harmoni PH lll-Trial – Ivonescimab combined with chemotherapy in patients with EGFR-mutant non-squamous NSCLC who progressed on EGFR tyrosine-kinase inhibitor treatment 
  • ALK 
    • Crown PH lll Study – Lobrena (lorlatinib) vs Xalkori (crizotinib) in patients who have not yet received treatment with advanced ALK+ NSCLC 
  • Small cell lung cancer (SCLC) 
    • DeLLphi-301 PH ll Trial – Imdeltra (tarlatamab-dlle) in SCLC 
  • Adjuvant therapy (resected EGFR-mutated, stage 2B-3A (lB-lllA)) 
    • ADAURA Trial – Molecular residual disease (MRD) analysis from the ADAURA trial of adjuvant Tagrisso (osimertinib) in patients with resected EGFR-mutated (EGFRm) stage 1B-3A (IB–IIIA) NSCLC 
  • Treatment outcomes 
    • ICARUS-LUNG01 PH ll Study – Datopotomab Deruxtecan (Dato-DXd) in patients with previously treated advanced NSCLC, with sequential tissue biopsies and biomarkers analysis to predict treatment outcome

Please join us on Sept. 17 at 5:30 p.m. PT/8:30 p.m. ET for the next Lung Cancer Living Room covering “What’s New in Radiation Therapy-New Advancements in Treatments.”  Join in person at our San Carlos, CA office or watch on YouTube Live.    

For more information on the Living Room, other GO2 for Lung Cancer programs, or support through diagnosis and treatment, please contact GO2’s HelpLine at 1-800-298-2436 or email support@go2.org.